Darolutamide Ups Survival in Metastatic Hormone-Sensitive Prostate Cancer
Adding darolutamide to ADT and docetaxel improves overall survival in patients with metastatic hormone-sensitive prostate cancer.
Adding darolutamide to ADT and docetaxel improves overall survival in patients with metastatic hormone-sensitive prostate cancer.
Men of African ancestry had the highest risk of developing metastatic prostate cancer when compared with men of other ancestries.
Investigators developed a multimodal deep learning architecture to learn from both clinicopathologic and digital imaging histopathology data and identify different outcomes by treatment type.
The risk of death from any cause was higher with degarelix.
Certain treatments were associated with an increased risk of death unrelated to testicular cancer.
Cancer patients had a low rate of seropositivity after the first vaccine dose but not after the second dose.
Active surveillance may help many men with favorable intermediate-risk prostate cancer to avoid the adverse effects of treatment for 5 years.
The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes and would benefit from a CGA.
Patients with GU malignancies were more likely to receive palliative care if they were in the West compared with other US regions.
Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.